Accessibility Menu
Calidi Biotherapeutics logo

Calidi Biotherapeutics(NYSEMKT) CLDI

Current Price$0.11
Market Cap$1.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 YearN/A
1 Year-99%
1 Month-36%
Calidi Biotherapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.102026-07-24
Calidi Biotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-15.9%USD 0.122026-07-17
1 month-36.31%USD 0.162026-06-24
3 month-55.75%USD 0.232026-04-24
Year to date-91.45%USD 1.172025-12-31
1 year-98.92%USD 9.262025-07-24
3 year-99.99%USD 1,264.202023-07-25
Since inception-99.99%USD 1,173.652021-11-01

Calidi Biotherapeutics Financials at a Glance

Market Cap

$1.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$19.03M

EPS (TTM)

-$5.18

P/E Ratio

-0.02

Dividend

$0.00

Beta (Volatility)

1.21 (Average)

Price

$0.11

Volume

24,355

Open

$0.10

Previous Close

$0.10

Daily Range

$0.10 - $0.11

52-Week Range

$0.10 - $10.92

Estimated Earnings Date

Aug 18, 2026

CLDI News

Foolcom-Featured.png

Calidi Loss Down 23 Percent in Fiscal Q2

Motley Fool Markets TeamAug 8, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Calidi Biotherapeutics

Calidi develops new cancer treatments using living cells to deliver anti-tumor agents. Its therapies aim to help patients with aggressive brain and solid tumors. The company’s work focuses on improving how cancer-fighting viruses reach and attack tumors.

Lab Bench to Bedside: Calidi’s Main Offerings

  • NeuroNova: Neural stem cells carrying a virus to treat high-grade brain tumors; no revenue contribution as of June 2025.
  • SuperNova: Fat-derived stem cells delivering a virus for advanced solid tumors; no revenue contribution as of June 2025.
  • RedTail: Engineered virus platform for delivering genetic medicines to tumors; no revenue contribution as of June 2025.

Growth and Expansion: Calidi’s Moves on the Board

  • Formed licensing partnerships with Northwestern University, City of Hope, and University of Chicago for technology and clinical data (years not specified).
  • Received FDA Fast Track Designation for SuperNova (CLD-201) in July 2025.
  • Expanded product pipeline with RedTail platform, targeting Phase 1 trials by late 2026.
  • Raised over $10 million through public and private equity offerings in the first half of 2025.
  • Operates subsidiaries in Germany and Australia, expanding beyond the US market.

What Makes Calidi Stand Out in the Crowd

Calidi uses stem cells to shield and deliver cancer-fighting viruses directly to tumors, aiming to improve treatment reach and safety. Its RedTail platform is designed for systemic delivery, potentially treating cancers that have spread throughout the body. Strategic academic partnerships support its research and clinical development.

Five Things You Need to Know

  • No revenue reported for Q2 2025; all focus is on research and development.
  • Net loss was $5.8 million in Q2 2025, unchanged from Q2 2024.
  • Cash and restricted cash totaled $5.4 million as of June 30, 2025, down 22.5% year-on-year.
  • Accumulated deficit reached $132.4 million as of June 30, 2025.
  • Management has raised concerns about the company’s ability to continue without new funding.

Bottom Line

Calidi remains focused on developing new cancer therapies using cell-based delivery systems. The company faces ongoing financial challenges as it advances its clinical pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

29

CEO

Eric E. Poma, PhD, MBA

Website

www.calidibio.com

Headquarters

San Diego, CA 92121, US

CLDI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-438.03%

Return on Capital

-320.10%

Return on Assets

-198.39%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

19.31M

Volume

24.36K

Avg. Volume

7.36M

Financials (TTM)

Gross Profit

-$426.00K

Operating Income

-$19.37M

EBITDA

-$17.24M

Operating Cash Flow

-$18.28M

Capital Expenditure

-$118.00K

Free Cash Flow

-$18.40M

Cash & ST Invst.

$6.63M

Total Debt

$2.26M

Calidi Biotherapeutics Performance Analysis

Calidi Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 45,000N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Calidi Biotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Calidi Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -358.76N/A
20232023-12-31USD -207.61-42.1%
20242024-12-31USD -35.70-82.8%
20252025-12-31USD -5.95-83.3%
Calidi Biotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3010.0%
Q32025-09-30-11.1%
Q42025-12-3174.7%
Q12026-03-3123.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$426.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$66.59K

N/A

Employees

29

N/A

Net Income

-$4.11M

+17.6%

EBITDA

-$3.64M

+20.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.63M

-37.2%

Total Debt

$2.26M

-52.0%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$753.00K

-66.6%

Short Term Debt

$1.50M

-38.7%

Return on Assets

-1.98%

N/A

Return on Invested Capital

-3.36%

N/A

Free Cash Flow

-$4.12M

+42.3%

Operating Cash Flow

-$4.12M

+42.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CMNDClearmind Medicine Inc.
$1.62+0.52%
SXTP60 Degrees Pharmaceuticals, Inc.
$1.50+1.32%
CNSPCNS Pharmaceuticals, Inc.
$5.19-0.76%
TTNPTitan Pharmaceuticals, Inc.
$2.34-11.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$63.06-0.01%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$45.44+0.01%
SKHYSK Hynix
$142.91-0.08%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.18+0.09%

Questions About CLDI

What is the current price of Calidi Biotherapeutics?

Calidi Biotherapeutics is trading at $0.11 per share.

What is the 52-week range for Calidi Biotherapeutics?

Over the past 52 weeks, Calidi Biotherapeutics has traded between $0.10 and $10.92.

How much debt does Calidi Biotherapeutics have?

As of the most recent reporting period, Calidi Biotherapeutics reported total debt of $2.26M.

How much cash does Calidi Biotherapeutics have on hand?

Calidi Biotherapeutics reported $6.73M in cash and cash equivalents in its most recent financial results.

What is Calidi Biotherapeutics’s dividend yield?

Calidi Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services